Richard A. Stein. Genetic Engineering & Biotechnology News. 2017. An advantage of the LODER platform is that it delivers RNAi locally, within the tumor, Circumventing systemic toxicity and the need for large systemically administered doses. “We have preclinical and clinical data showing that our treatment is safe,” asserts Dr. Shemi.
Ricardo Titze-de-Almeida, Catherine David & Simoneide Souza Titze-de-Almeida. Pharmaceutical Research. 2017. “KRAS-LODER made KRAS a druggable anticancer target. New drugs also targeting this oncogene are now in test and may represent future competitors of KRAS-LODER. KRAS-LODER is the only RNAi-based drug that provides a sustained release of siRNA into the tumor
Benjamin A. Krantz, Kenneth H. Yu, Eileen M. O’Reilly. Chinese Clinical Oncology. 2017. “Targeting RAS by inhibiting translation using small-interfering RNAs is a novel strategy to decrease RAS activity. siRNA against the G12D mutant RAS RNA by local prolonged delivery, KRAS-LODER (Local Drug EluteR), has demonstrated decreased growth of human pancreatic
Israeli drug development company Silenseed is to begin a Phase II multicenter trial for its pancreatic cancer treatment. The study, which has been approved by the US Food and Drug Administration (FDA), will be held at several leading medical centers in the US with the participation of 80 patients. At